Revotar Biopharmaceuticals AG has been awarded funding of the German Federal Ministry of Education and Research
Revotar Biopharmaceuticals AG announced that it has been awarded funding of the German Federal Ministry of education and Research (BMBF) to intensify its selectin antagonist discovery programme. The funding totals 427.987 Euros and will be paid over a two-year period. The funding will be provided by the "BioChancePLUS-2" programme of the BMBF and supports Revotar´s activites to design novel anti-inflammatory selectin antagonists to be developed for the treatment of Chronic Obstructive Pulmonary Disease (COPD).
The project is headed by Gerhard Wolff, M.D., Vice President R&D of Revotar, assisted by Ewald Aydt, Ph.D., Director Discovery of Revotar. The project is a significant contribution to Revotar`s strategy to develop selectin antagonists as small molecule drugs (SMD) for inflammatory diseases, stated Stephan Tarlach, CEO of Revotar. In addition, the awarded funding reflects the contineously growing confidence in the business concept of Revotar, added Marc Voigt, CFO of Revotar.
Most read news
Organizations
Other news from the department science
![Newsletter](https://img.chemie.de/assets/bionity/images/newsletter.png)
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.